CA

Cardiogeni Plc

Developing engineered cellular medicines for regenerative treatment of heart failure.

Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BTBLFC12
LEI:
9845000F8F59ATZD8F92
Country:
United Kingdom
Address:
Celixir House Stratford-Upon-Avon Business & Technology Park, CV37 7GZ Stratford-Upon-Avon
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Cardiogeni Plc is a clinical-stage biotechnology company, founded by Nobel Laureate Professor Sir Martin Evans, that focuses on developing next-generation treatments for heart failure. The company specializes in regenerative medicine, utilizing a proprietary platform technology to create engineered cellular medicines. These therapies are designed to treat patients with heart failure, particularly those undergoing coronary artery bypass surgery. Cardiogeni's lead product candidate is CLXR-001. The company's mission is to become a market leader in heart failure regeneration by developing a new class of life-saving treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 18:51
Annual Report
Annual Results to 31 March 2025
English 129.7 KB
2025-07-24 17:45
Share Issue/Capital Change
Details of Advanced Subscription & Company Update
English 21.0 KB
2025-07-24 08:00
Capital/Financing Update
£150,000 Advanced Subscription Agreement
English 14.2 KB
2025-07-02 08:00
Regulatory News Service
Appointment of corporate broker
English 11.6 KB

Automate Your Workflow. Get a real-time feed of all Cardiogeni Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cardiogeni Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN
Aladdin Healthcare Technologies SE Logo
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany NMI
Alten Logo
Global engineering and IT consulting for digital transformation in industry and telecom sectors.
France ATE
Amoéba Logo
Develops amoeba-based natural fungicides for agriculture and active ingredients for cosmetics.
France ALMIB
APTAMER GROUP PLC Logo
Develops custom aptamer-based binders as antibody alternatives for life science applications.
United Kingdom APTA
Aran Research & Development (1982) Ltd. Logo
End-to-end product & machine development for plastics, medical, and industrial markets.
Israel ARAN
ARIX BIOSCIENCE PLC Logo United Kingdom ARIX
Asarina Pharma AB Logo
Developed Sepranolone for neurological disorders like Tourette's, OCD, and menstrual migraine.
Sweden ASAP

Talk to a Data Expert

Have a question? We'll get back to you promptly.